Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-22-028157
Filing Date
2022-02-28
Accepted
2022-02-28 17:01:13
Documents
1
Period of Report
2022-02-25

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm227910-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm227910-1_4seq1.xml 4 3750
  Complete submission text file 0001104659-22-028157.txt   5355
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Issuer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 L3 20100
Business Address
Bashan Dror (Reporting) CIK: 0001781450 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-33357 | Film No.: 22690977